Literature DB >> 3786824

An analysis of prognostic factors in early stage Hodgkin's disease.

A Horwich, D Easton, R Nogueira-Costa, K H Liew, M Colman, M J Peckham.   

Abstract

An analysis of prognostic factors has been carried out in 398 patients presenting with clinical Stage I and II Hodgkin's disease treated between 1963 and 1979. By life table analysis older age, lymphocyte depletion histology, systemic symptoms, mediastinal node bulk, and erythrocyte sedimentation rate (ESR) greater than 40 mm/h were associated with a significantly worse survival probability. On multiple factor regression analysis only age and stage were independent prognostic variables for survival, with systemic symptoms having borderline significance. Using this information, together with other analyses of prognosis in early Hodgkin's disease three groups of patients are defined. The first with a predicted 5-year survival of 78% would include patients possessing at least one of the following features; age greater than 60, lymphocyte depletion, greater than 3 sites involved, systemic symptoms, mediastinal/thoracic ratio of greater than 1/3. The second groups present with at least two of the following factors; ESR greater than 40 mm/h, male sex, 3 involved sites, or mixed cellularity histology, and the 5 year survival probability is 84%. The remaining Stage I and II patients would constitute a good prognosis group with a predicted 5-year survival of 92%.

Entities:  

Mesh:

Year:  1986        PMID: 3786824     DOI: 10.1016/s0167-8140(86)80089-5

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

Review 1.  Early stage Hodgkin's disease in adults: which is the correct treatment?

Authors:  M Brada
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

2.  Changing patterns of relapse in Hodgkin's disease.

Authors:  G Duchesne; J Crow; S Ashley; M Brada; A Horwich
Journal:  Br J Cancer       Date:  1989-08       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.